Drug Profile
XL 418
Alternative Names: EXEL 9418; XL-418Latest Information Update: 26 Feb 2008
Price :
$50
*
At a glance
- Originator Exelixis
- Class Antineoplastics; Small molecules
- Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 05 Dec 2007 Discontinued - Phase-I for Solid tumours in USA (PO)
- 01 May 2007 Phase-I clinical trials in Solid tumours in USA (PO)
- 30 Jan 2007 Preclinical trials in Solid tumours in USA (PO)